Sunita M C De Sousa1,2,3, Nisa Sheriff4,5, Chau H Tran4,6, Alexander M Menzies7,8,9,10, Venessa H M Tsang8,10,11, Georgina V Long7,8,9,10, Katherine T T Tonks12,13,14,15. 1. Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, Australia. 2. Department of Genetics and Molecular Pathology, Centre for Cancer Biology, an SA Pathology and University of South Australia Alliance, Adelaide, Australia. 3. School of Medicine, University of Adelaide, Adelaide, Australia. 4. Department of Endocrinology, St Vincent's Hospital, Darlinghurst, Australia. 5. Diabetes and Metabolism Program, Garvan Institute of Medical Research, Darlinghurst, Australia. 6. St Vincent's Clinical School, University of New South Wales, Sydney, Australia. 7. Melanoma Institute Australia, Wollstonecraft, Australia. 8. Royal North Shore Hospital, St Leonards, Australia. 9. University of Sydney, Camperdown, Australia. 10. Mater Hospital, North Sydney, Australia. 11. Kolling Institute of Medical Research, St Leonards, Australia. 12. Department of Endocrinology, St Vincent's Hospital, Darlinghurst, Australia. k.tonks@garvan.org.au. 13. Diabetes and Metabolism Program, Garvan Institute of Medical Research, Darlinghurst, Australia. k.tonks@garvan.org.au. 14. St Vincent's Clinical School, University of New South Wales, Sydney, Australia. k.tonks@garvan.org.au. 15. Mater Hospital, North Sydney, Australia. k.tonks@garvan.org.au.
Abstract
PURPOSE: Hypophysitis develops in up to 19% of melanoma patients treated with ipilimumab, a cytotoxic T-lymphocyte antigen-4 antibody. Early detection may avert life-threatening hypopituitarism. We aimed to assess the incidence of ipilimumab-induced hypophysitis (IH) at a quaternary melanoma referral centre, and to determine whether cortisol or thyroid stimulating hormone (TSH) monitoring could predict IH onset. METHODS: We performed a retrospective cohort study of ipilimumab-treated patients at a quaternary melanoma referral centre in Australia. The inclusion criteria were patients with metastatic or unresectable melanoma treated with ipilimumab monotherapy, and cortisol and TSH measurements prior to ≥ 2 infusions. The main outcomes were IH incidence and TSH and cortisol patterns in patients who did and did not develop IH. RESULTS: Of 78 ipilimumab-treated patients, 46 met the study criteria and 9/46 (20%) developed IH at a median duration of 13.0 weeks (range 7.7-18.1) following ipilimumab initiation. All patients whose TSH fell ≥ 80% compared to baseline developed IH, and, in 5/9 patients with IH, TSH fell prior to cortisol fall and IH diagnosis. Pre-cycle-4 TSH was significantly lower in those who developed IH (0.31 vs. 1.73 mIU/L, P = 0.006). TSH fall was detected at a median time of 9.2 (range 7.7-16.4) weeks after commencing ipilimumab, and a median of 3.6 (range of - 1.4 to 9.7) weeks before IH diagnosis. There was no difference in TSH between the groups before cycles 1-3 or in cortisol before cycles 1-4. CONCLUSIONS: TSH fall ≥ 80% may be an early marker of IH. Serial TSH measurement during ipilimumab therapy may be an inexpensive tool to expedite IH diagnosis.
PURPOSE:Hypophysitis develops in up to 19% of melanomapatients treated with ipilimumab, a cytotoxic T-lymphocyte antigen-4 antibody. Early detection may avert life-threatening hypopituitarism. We aimed to assess the incidence of ipilimumab-induced hypophysitis (IH) at a quaternary melanoma referral centre, and to determine whether cortisol or thyroid stimulating hormone (TSH) monitoring could predict IH onset. METHODS: We performed a retrospective cohort study of ipilimumab-treated patients at a quaternary melanoma referral centre in Australia. The inclusion criteria were patients with metastatic or unresectable melanoma treated with ipilimumab monotherapy, and cortisol and TSH measurements prior to ≥ 2 infusions. The main outcomes were IH incidence and TSH and cortisol patterns in patients who did and did not develop IH. RESULTS: Of 78 ipilimumab-treated patients, 46 met the study criteria and 9/46 (20%) developed IH at a median duration of 13.0 weeks (range 7.7-18.1) following ipilimumab initiation. All patients whose TSH fell ≥ 80% compared to baseline developed IH, and, in 5/9 patients with IH, TSH fell prior to cortisol fall and IH diagnosis. Pre-cycle-4 TSH was significantly lower in those who developed IH (0.31 vs. 1.73 mIU/L, P = 0.006). TSH fall was detected at a median time of 9.2 (range 7.7-16.4) weeks after commencing ipilimumab, and a median of 3.6 (range of - 1.4 to 9.7) weeks before IH diagnosis. There was no difference in TSH between the groups before cycles 1-3 or in cortisol before cycles 1-4. CONCLUSIONS: TSH fall ≥ 80% may be an early marker of IH. Serial TSH measurement during ipilimumab therapy may be an inexpensive tool to expedite IH diagnosis.
Authors: Mabel Ryder; Margaret Callahan; Michael A Postow; Jedd Wolchok; James A Fagin Journal: Endocr Relat Cancer Date: 2014-03-07 Impact factor: 5.678
Authors: Le Min; Frank Stephen Hodi; Anita Giobbie-Hurder; Patrick A Ott; Jason J Luke; Hilary Donahue; Meredith Davis; Rona S Carroll; Ursula B Kaiser Journal: Clin Cancer Res Date: 2014-12-23 Impact factor: 12.531
Authors: T Lam; M M K Chan; A N Sweeting; S M C De Sousa; A Clements; M S Carlino; G V Long; K Tonks; E Chua; R F Kefford; D R Chipps Journal: Intern Med J Date: 2015-10 Impact factor: 2.048
Authors: Stephanie G Downey; Jacob A Klapper; Franz O Smith; James C Yang; Richard M Sherry; Richard E Royal; Udai S Kammula; Marybeth S Hughes; Tamika E Allen; Catherine L Levy; Michael Yellin; Geoffrey Nichol; Donald E White; Seth M Steinberg; Steven A Rosenberg Journal: Clin Cancer Res Date: 2007-11-02 Impact factor: 12.531
Authors: Shintaro Iwama; Alessandra De Remigis; Margaret K Callahan; Susan F Slovin; Jedd D Wolchok; Patrizio Caturegli Journal: Sci Transl Med Date: 2014-04-02 Impact factor: 17.956
Authors: Alexander T Faje; Ryan Sullivan; Donald Lawrence; Nicholas A Tritos; Riley Fadden; Anne Klibanski; Lisa Nachtigall Journal: J Clin Endocrinol Metab Date: 2014-07-31 Impact factor: 5.958
Authors: Salahaldin A Tahir; Jianjun Gao; Yuji Miura; Jorge Blando; Rebecca S S Tidwell; Hao Zhao; Sumit K Subudhi; Hussein Tawbi; Emily Keung; Jennifer Wargo; James P Allison; Padmanee Sharma Journal: Proc Natl Acad Sci U S A Date: 2019-10-14 Impact factor: 11.205
Authors: M S Siddiqui; Z M Lai; L Spain; V Greener; S Turajlic; J Larkin; D L Morganstein Journal: J Endocrinol Invest Date: 2020-05-24 Impact factor: 4.256
Authors: Julie R Brahmer; Hamzah Abu-Sbeih; Paolo Antonio Ascierto; Jill Brufsky; Laura C Cappelli; Frank B Cortazar; David E Gerber; Lamya Hamad; Eric Hansen; Douglas B Johnson; Mario E Lacouture; Gregory A Masters; Jarushka Naidoo; Michele Nanni; Miguel-Angel Perales; Igor Puzanov; Bianca D Santomasso; Satish P Shanbhag; Rajeev Sharma; Dimitra Skondra; Jeffrey A Sosman; Michelle Turner; Marc S Ernstoff Journal: J Immunother Cancer Date: 2021-06 Impact factor: 13.751